The pharmaceutical company “JSC Galichpharm” (Lviv) produced 3.934 million packages of finished pharmaceutical products in the second quarter of 2026, worth approximately 981.424 million UAH.
According to the company’s disclosure in the National Securities and Stock Market Commission (NSSMC) disclosure system, the average cost per package of medicines is 213.18 UAH for injectables, 52.11 UAH for infusions, 117.25 UAH for liquids and syrups, and 52.6 UAH for tablets.
Galichpharm’s total revenue for the second quarter of 2026 amounted to 354.394 million UAH. Total exports reached 115.4 million UAH, or 48.3% of total sales.
Currently, the company supplies products to the Ukrainian market and exports them to Kazakhstan, Uzbekistan, Latvia, Australia, and other countries.
As previously reported, “Galichpharm” (Lviv) produced 22.098 million packages of medicines in 2025 and sold finished products worth 1.774 billion UAH. The company then reported a net loss of 1.151 billion UAH, compared to a net profit of 13.705 million UAH in 2024 (-39% compared to 2023).
As previously reported, in May 2025, the Commercial Court of Lviv Oblast opened bankruptcy proceedings against the pharmaceutical manufacturer JSC “Galichpharm” based on claims filed by LLC “Sky-Development” in the amount of 479.262 million UAH. On April 21, 2025, Sky-Development LLC acquired from JSC “Bank Finansy i Kredit” the rights to claims against JSC “Galichpharm” under loan agreements and security agreements.
The investment company “Sky-Development” won an open auction organized by the Deposit Guarantee Fund for Individuals and acquired the claims of the insolvent JSC “Bank ‘Finansy i Kredit’” under ten loan agreements with leading Ukrainian pharmaceutical companies: JSC “Galichpharm” and JSC “Kyivmedpreparat.” According to Sky Development, the total amount of its claims exceeds 3.5 billion UAH.
For their part, “Kyivmedpreparat” and “Galichpharm” stated that the information disseminated by Sky Development Investment Company is “inaccurate, manipulative, and shows signs of a deliberate attempt to discredit the companies’ operations.” In particular, both companies denied having “multi-billion debts” to “Sky Development.” The pharmaceutical companies characterized the statements by “Sky Development” LLC as “an attempt to illegally and artificially create non-existent creditor debt for a possible future hostile takeover of the companies.”
EXPORTS, Galichpharm, MANUFACTURING, MEDICINES, PHARMACEUTICALS
